Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20 CAR-T in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT04169932Phase 1Unknown
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY007 in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Longyao Biotechnology Co., Ltd. Primary endpoints: Adverse events (AEs) at 4 weeks, Expression of CD20 CART cells at 2 years and 2 more. Status: unknown.
02
Drugs
LY007
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04169932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169932.